©Viva Biotech (Shanghai) Ltd. 沪ICP备12042930号   Powerd by 

Company News
Viva Biotech was invited to attend the 40th Annual J.P. Morgan Health Care Conference, 2022
Dr. Han Dai Viva Biotech's world-leading one-stop drug R&D and production services and future strategies, and Highlighted the development and strategies of EFS investment and Incubation services.
Viva Biotech Upcoming Conferences & Events
In the near future, Viva Biotech will attend 8 industry conferences/events.
ABM Therapeutics Completes $30 Million Series B Financing
The funds will be used to accelerate the clinical research of ABM-1310 in China and the U.S., develop several existing preclinical projects, and build the company's pipeline and the management team.
Portfolio Highlights: Clinical and Financing Updates of VivaVision, QureBio, AlxplorerBio and BIOCAST
Over the past 1 month, our portfolio companies have had great progress.
AlxplorerBio and AliveX, BIOCAST Reached a Strategic Collaboration Agreement, To Jointly Promote the Development of Precision Medicines of IBD
The collaboration integrates the strengths of the three companies to jointly promote the development of precision medicines of IBD, preclinical studies, and IND enabling in China and the U.S.
Page up